First AD

Second AD

Insight regarding updates to the management of patients with colorectal cancer who are microsatellite instability-high (MSI-H)/mismatch repair deficient, harbor a 

Data from the following clinical trials is discussed:

Pembrolizumab vs chemotherapy for MSI-H/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. (Andre T, et al. ASCO 2020. LBA4)

Encorafenib plus cetuximab +/- binimetinib for 

 V600E metastatic colorectal cancer: BEACON CRC updated survival results (Kopetz S, et al. ASCO 2020. Abstract 4001)

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with 

-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (Siena S, et al. ASCO 2020. Abstract 4000)

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Colorectal Cancer Updates

Data from the following clinical trials is discussed:

Pembrolizumab vs chemotherapy for MSI-H/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. (Andre T, et al. ASCO 2020. LBA4)

Encorafenib plus cetuximab +/- binimetinib for BRAF V600E metastatic colorectal cancer: BEACON CRC updated survival results (Kopetz S, et al. ASCO 2020. Abstract 4001)

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (Siena S, et al. ASCO 2020. Abstract 4000)